tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate

We are tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate CAS:571189-16-7 manufacturer and supplier in China, we can offer the best quality and price of tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests, thank you!

Chemical Name:tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate
CAS.NO:571189-16-7
Synonyms:4-(6-nitro-pyridin-3-yl)-piperazine-1-carboxylic acid tert-butyl ester
4-(6-nitro-3-pyridinyl)-1-piperazinecarboxylic acid,1,1-dimethylethyl ester
Molecular Formula:C14H20N4O4
Molecular Weight:308.33300
 
Physical and Chemical Properties:
Density:1.258
Boiling point:480.1ºC
Flash point:244.1ºC
Index of Refraction:1.562
 
Specification:
Appearance:Off-white to orange crystal or powder
Assay:≥98.0%
Loss on drying:≤1.0%
Single impurity:≤1.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediates of Palbociclib
 
Note:The product under valid patents will not be offered to the countries covered by patents.

tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate


Related News: Among them, Zhejiang pharmaceutical companies accounted for 4 of the world’s top ten API manufacturers.2-cloroanisol CAS:766-51-8 Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations.2-Amino-5-bromo-3-methylpyridine CAS:3430-21-5 Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations.328-80-3 Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).Over the past twelve months, the collaboration team has worked to optimize its processes for making T cells from iPSCs, and has now shown the production of pure T-lymphocytes consisting of both CD8+ and CD4+ T cells having a global gene expression profile that is highly-similar to primary T cells based on a principal component analysis.

Related Products
Product Name
(4R,5S)-5-(3,5-bis(trifluoroMethyl)phenyl)-4-Methyloxazolidin-2-one View Details
6-Quinolinecarboxylic acid, 4-chloro-7-methoxy-, methyl ester View Details
N,N’-bis(4-bromophenyl)-N,N’-bis(4-methylphenyl)-[1,1′-Biphenyl]-4,4′-diamine View Details
5-bromopyridine-3-carbonitrile manufacturer Ethyl 2-chloroacetoacetate manufacturer 3-Nitro-N-(2-Hydroxypropyl)-4-Aminophenol manufacturer 1-Bromoheptane manufacturer 3-[2-(4-chlorophenoxy)phenyl]-1-methylpyrrolidine-2,4-dione manufacturer